Ex-Patent Rights Holders Want $20M Skin Drug Suit Revived
Former shareholders of a pharmaceutical company that held patent rights for skin medication Brimonidine have asked a Pennsylvania state judge to reconsider a decision ending a $20 million suit against current...To view the full article, register now.
Already a subscriber? Click here to view full article